Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Impax Laboratories, a specialty pharmaceutical company, has announced that beginning July 1, 2009, Impax Pharmaceuticals, the company's specialty brand products division will co-promote Wyeth's Pristiq.
Subscribe to our email newsletter
Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a treatment for adult patients with major depressive disorder.
As previously announced, Impax Laboratories entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by Wyeth for neurologists. Impax will receive a fee for each detail delivered. Other terms of this agreement are confidential and were not disclosed.